問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

童建學
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

23Cases

2014-03-14 - 2020-07-22

Phase IV

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS
  • Condition/Disease

    rheumatoid arthritis

  • Test Drug

    Xeljanz

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

2012-12-01 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-06-01 - 2015-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Study ended2Sites

1 2 3